- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Christopher Kane Explains How MRI Is Influencing Prostate Cancer Diagnosis
Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego.
Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and we think there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego.
Transcript (slightly modified)
How is MRI influencing prostate cancer diagnosis?
I think magnetic resonance imaging (MRI) has been 1 of the big changes over the last 5 years. The first place that MRI really makes a difference is in studying men who’ve had previous prostate biopsy, and that biopsy was negative, and overtime their prostate-specific antigen (PSA) goes up or something changes and we think there’s a continuing concern for prostate cancer. Now, we routinely do an MRI before we do a repeat biopsy, and if we see regions that are suspicious for high-grade prostate cancer, we adjust the biopsy to make sure we hit those regions, and that’s called targeted biopsy. That very much improves the outcome of repeat prostate biopsy.
So, we’ve known that and it’s been in our guidelines for more than 5 years, and what’s technology, and now we’re wondering, “Gee, if I have a man and we’re going to recommend a prostate biopsy based on PSA or family history or rectal exam, shouldn’t we do an MRI prior to similarly improve the performance of our biopsy?”
I think many of our programs that are using MRI more liberally are wondering whether we can improve the performance of the initial prostate biopsy by doing an MRI, and that’s an area of controversy not yet in the guidelines. The big controversy is that if we do this is that we’re going to increase costs of the screening episode, and is that justified by the marginal improvement in diagnostics.
That’s the subject of a number of clinical trials. It was the subject of the session this morning. A debate between Professor Emberton and Dr Pedrosa about where is MRI moving, and I think 1 of the places it’s likely moving is earlier, meaning for the initial prostate biopsy.
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More
